Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
small cell lung cancer
Biotech
Merck inks $680M Harpoon buyout to challenge Amgen
Merck will gain control of molecules that will expand its cancer pipeline and offer opportunities to offset the upcoming loss of Keytruda exclusivity.
Nick Paul Taylor
Jan 8, 2024 8:41am
Amgen details ph. 2 tarlatamab data in patients with SCLC
Oct 20, 2023 11:30am
AstraZeneca, Daiichi show off ADCs with safety top of mind
Sep 11, 2023 9:58am
Mariana reels in $175M for radiopharmaceutical pipeline
Sep 7, 2023 10:45am
Amgen's tarlatamab BiTEs at SCLC in brief readout
Aug 3, 2023 4:01pm
Puma pounces on failed Takeda drug, snapping up cancer prospect
Sep 21, 2022 9:05am